{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T13:10:07Z","timestamp":1794661807853,"version":"4.9.1"},"reference-count":37,"publisher":"American Society of Hematology","issue":"2","license":[{"start":{"date-parts":[[2024,9,18]],"date-time":"2024-09-18T00:00:00Z","timestamp":1726617600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,1,28]]},"abstract":"<jats:sec>\n                  <jats:title>Abstract<\/jats:title>\n                  <jats:p>The B-cell lymphoma 2 inhibitor venetoclax (VEN) in combination with hypomethylating agents has been approved for first-line treatment of patients with acute myeloid leukemia (AML) ineligible for intensive treatment. VEN-containing treatment strategies may also be effective in relapsed\/refractory (R\/R) AML; however, comparative studies with conventional therapies for fit patients as a bridge-to-transplant strategy are limited. Using propensity score matching (PSM), we compared 37 patients with R\/R AML, who received VEN-based salvage therapy as bridge to allogeneic hematopoietic stem cell transplantation (allo-HCT), with 90 patients from the German Study Alliance Leukemia AML registry, who were treated with non\u2013VEN-containing salvage therapy according to their treating physician\u2019s choice (TPC). The overall response rate among VEN patients was higher than the TPC control cohort (62% vs 42%; P\u00a0=\u00a0.049). Overall, 73% of VEN-treated patients vs 63% of TPC patients were bridged to allo-HCT (P\u00a0=\u00a0.41). After a median follow-up of 34.3\u00a0months for the VEN and 21.0\u00a0months for the TPC cohort, the median overall survival (OS) were 15.8\u00a0months (95% confidence interval [CI], 10.6 to not evaluable) and 10.5\u00a0months (95%\u00a0CI, 6.8-19.6; P\u00a0=\u00a0.15), respectively. PSM revealed a trend toward improved OS for VEN patients (hazard ratio, 0.70; 95%\u00a0CI, 0.41-1.22; P\u00a0=\u00a0.20). Median event-free survival was significantly longer in the VEN cohort (8.0\u00a0months) than the TPC cohort (3.7\u00a0months; P\u00a0=\u00a0.006). Our data suggest that VEN-based salvage therapy is a safe and effective bridge to allo-HCT for this difficult-to-treat AML patient population.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1182\/bloodadvances.2024013086","type":"journal-article","created":{"date-parts":[[2024,9,18]],"date-time":"2024-09-18T21:17:38Z","timestamp":1726694258000},"page":"375-385","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":19,"title":["Venetoclax-based salvage therapy as a bridge to transplant is feasible and effective in patients with relapsed\/refractory AML"],"prefix":"10.1182","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3577-5493","authenticated-orcid":false,"given":"Julia M.","family":"Unglaub","sequence":"first","affiliation":[{"name":"1Department of Hematology, Oncology and Rheumatology, University Hospital Heidelberg, Heidelberg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2215-2059","authenticated-orcid":false,"given":"Richard F.","family":"Schlenk","sequence":"additional","affiliation":[{"name":"1Department of Hematology, Oncology and Rheumatology, University Hospital Heidelberg, Heidelberg, Germany"},{"name":"2National Center of Tumor Diseases, Heidelberg University Hospital and German Cancer Research Center, Heidelberg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan Moritz","family":"Middeke","sequence":"additional","affiliation":[{"name":"3Department of Internal Medicine I, University Hospital TU Dresden, Dresden, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5259-4651","authenticated-orcid":false,"given":"Stefan W.","family":"Krause","sequence":"additional","affiliation":[{"name":"4Department of Hematology and Medical Oncology, University Hospital Erlangen, Erlangen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabrina","family":"Kraus","sequence":"additional","affiliation":[{"name":"5Department of Internal Medicine II, University Hospital W\u00fcrzburg, W\u00fcrzburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hermann","family":"Einsele","sequence":"additional","affiliation":[{"name":"5Department of Internal Medicine II, University Hospital W\u00fcrzburg, W\u00fcrzburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Kramer","sequence":"additional","affiliation":[{"name":"3Department of Internal Medicine I, University Hospital TU Dresden, Dresden, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1811-4562","authenticated-orcid":false,"given":"Sven","family":"Zukunft","sequence":"additional","affiliation":[{"name":"3Department of Internal Medicine I, University Hospital TU Dresden, Dresden, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1632-0167","authenticated-orcid":false,"given":"Joseph","family":"Kauer","sequence":"additional","affiliation":[{"name":"1Department of Hematology, Oncology and Rheumatology, University Hospital Heidelberg, Heidelberg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon","family":"Renders","sequence":"additional","affiliation":[{"name":"1Department of Hematology, Oncology and Rheumatology, University Hospital Heidelberg, Heidelberg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Katelari","sequence":"additional","affiliation":[{"name":"1Department of Hematology, Oncology and Rheumatology, University Hospital Heidelberg, Heidelberg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"Schliemann","sequence":"additional","affiliation":[{"name":"6Department of Medicine A, University Hospital M\u00fcnster, M\u00fcnster, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9716-5909","authenticated-orcid":false,"given":"Caroline","family":"Pabst","sequence":"additional","affiliation":[{"name":"1Department of Hematology, Oncology and Rheumatology, University Hospital Heidelberg, Heidelberg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Luft","sequence":"additional","affiliation":[{"name":"1Department of Hematology, Oncology and Rheumatology, University Hospital Heidelberg, Heidelberg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7429-8570","authenticated-orcid":false,"given":"Peter","family":"Dreger","sequence":"additional","affiliation":[{"name":"1Department of Hematology, Oncology and Rheumatology, University Hospital Heidelberg, Heidelberg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3791-0548","authenticated-orcid":false,"given":"Christoph","family":"R\u00f6llig","sequence":"additional","affiliation":[{"name":"3Department of Internal Medicine I, University Hospital TU Dresden, Dresden, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5916-3029","authenticated-orcid":false,"given":"Martin","family":"Bornh\u00e4user","sequence":"additional","affiliation":[{"name":"3Department of Internal Medicine I, University Hospital TU Dresden, Dresden, Germany"},{"name":"7National Center for Tumor Diseases Dresden, Dresden, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7166-5232","authenticated-orcid":false,"given":"Carsten","family":"M\u00fcller-Tidow","sequence":"additional","affiliation":[{"name":"1Department of Hematology, Oncology and Rheumatology, University Hospital Heidelberg, Heidelberg, Germany"},{"name":"8Molecular Medicine Partnership Unit, Heidelberg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5412-324X","authenticated-orcid":false,"given":"Tim","family":"Sauer","sequence":"additional","affiliation":[{"name":"1Department of Hematology, Oncology and Rheumatology, University Hospital Heidelberg, Heidelberg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2025,1,17]]},"reference":[{"issue":"12","key":"2025012813454232600_bib1","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1182\/blood.2022016867","article-title":"Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN","volume":"140","author":"D\u00f6hner","year":"2022","journal-title":"Blood"},{"issue":"6","key":"2025012813454232600_bib2","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1038\/s41375-023-01884-2","article-title":"Validation and refinement of the 2022 European LeukemiaNet genetic risk stratification of acute myeloid leukemia","volume":"37","author":"Rausch","year":"2023","journal-title":"Leukemia"},{"issue":"9","key":"2025012813454232600_bib3","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1182\/blood.2019001982","article-title":"How I treat relapsed or refractory AML","volume":"136","author":"DeWolf","year":"2020","journal-title":"Blood"},{"issue":"2","key":"2025012813454232600_bib4","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1111\/j.1365-2141.2009.07917.x","article-title":"Failure of three novel regimens to improve outcome for patients with relapsed or refractory acute myeloid leukaemia: a report from the Eastern Cooperative Oncology Group","volume":"148","author":"Litzow","year":"2010","journal-title":"Br J Haematol"},{"issue":"5","key":"2025012813454232600_bib5","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1038\/leu.2017.22","article-title":"Impact of pretreatment characteristics and salvage strategy on outcome in patients with relapsed acute myeloid leukemia","volume":"31","author":"Schlenk","year":"2017","journal-title":"Leukemia"},{"issue":"6","key":"2025012813454232600_bib6","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1038\/leu.2017.23","article-title":"Impact of salvage regimens on response and overall survival in acute myeloid leukemia with induction failure","volume":"31","author":"Wattad","year":"2017","journal-title":"Leukemia"},{"issue":"3","key":"2025012813454232600_bib7","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1182\/blood-2014-10-551911","article-title":"How I treat refractory and early relapsed acute myeloid leukemia","volume":"126","author":"Thol","year":"2015","journal-title":"Blood"},{"issue":"2","key":"2025012813454232600_bib8","doi-asserted-by":"crossref","first-page":"342","DOI":"10.3324\/haematol.2022.280802","article-title":"Update on current treatments for adult acute myeloid leukemia: to treat acute myeloid leukemia intensively or non-intensively? That is the question","volume":"108","author":"Jaramillo","year":"2023","journal-title":"Haematologica"},{"issue":"2","key":"2025012813454232600_bib9","doi-asserted-by":"crossref","first-page":"306","DOI":"10.3324\/haematol.2022.280803","article-title":"Acute myeloid leukemia: introduction to a series highlighting progress and ongoing challenges","volume":"108","author":"Schlenk","year":"2023","journal-title":"Haematologica"},{"issue":"1","key":"2025012813454232600_bib10","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1038\/nrm3722","article-title":"Control of apoptosis by the BCL-2 protein family: implications for physiology and therapy","volume":"15","author":"Czabotar","year":"2014","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"12","key":"2025012813454232600_bib11","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1158\/2159-8290.CD-17-0797","article-title":"Found in translation: how preclinical research is guiding the clinical development of the BCL2-selective inhibitor venetoclax","volume":"7","author":"Leverson","year":"2017","journal-title":"Cancer Discov"},{"issue":"7","key":"2025012813454232600_bib12","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1056\/NEJMoa2012971","article-title":"Azacitidine and venetoclax in previously untreated acute myeloid leukemia","volume":"383","author":"DiNardo","year":"2020","journal-title":"N\u00a0Engl J Med"},{"issue":"1","key":"2025012813454232600_bib13","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1182\/blood-2018-08-868752","article-title":"Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia","volume":"133","author":"DiNardo","year":"2019","journal-title":"Blood"},{"issue":"15","key":"2025012813454232600_bib14","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1200\/JCO.18.01600","article-title":"Venetoclax combined with low-dose cytarabine for previously untreated patients with acute myeloid leukemia: results from a phase Ib\/II study","volume":"37","author":"Wei","year":"2019","journal-title":"J\u00a0Clin Oncol"},{"issue":"1","key":"2025012813454232600_bib15","doi-asserted-by":"crossref","first-page":"22","DOI":"10.3390\/cancers14010022","article-title":"Venetoclax in relapsed\/refractory acute myeloid leukemia: are supporting evidences enough?","volume":"14","author":"Brancati","year":"2021","journal-title":"Cancers"},{"issue":"4","key":"2025012813454232600_bib16","doi-asserted-by":"crossref","DOI":"10.1097\/HS9.0000000000000549","article-title":"Safety and efficacy: clinical experience of venetoclax in combination with hypomethylating agents in both newly diagnosed and relapsed\/refractory advanced myeloid malignancies","volume":"5","author":"Feld","year":"2021","journal-title":"Hemasphere"},{"issue":"11","key":"2025012813454232600_bib17","doi-asserted-by":"crossref","first-page":"3191","DOI":"10.1007\/s00432-022-03930-5","article-title":"Clinical experience with venetoclax in patients with newly diagnosed, relapsed, or refractory acute myeloid leukemia","volume":"148","author":"Fleischmann","year":"2022","journal-title":"J\u00a0Cancer Res Clin Oncol"},{"issue":"9","key":"2025012813454232600_bib18","doi-asserted-by":"crossref","first-page":"e404","DOI":"10.3324\/haematol.2018.188094","article-title":"Efficacy of the combination of venetoclax and hypomethylating agents in relapsed\/refractory acute myeloid leukemia","volume":"103","author":"Aldoss","year":"2018","journal-title":"Haematologica"},{"issue":"8","key":"2025012813454232600_bib19","doi-asserted-by":"crossref","first-page":"2025","DOI":"10.3390\/cancers14082025","article-title":"Azacitidine plus venetoclax for the treatment of relapsed and newly diagnosed acute myeloid leukemia patients","volume":"14","author":"Garciaz","year":"2022","journal-title":"Cancers"},{"issue":"7","key":"2025012813454232600_bib20","doi-asserted-by":"crossref","first-page":"1734","DOI":"10.3390\/cancers14071734","article-title":"Use of venetoclax in patients with relapsed or refractory acute myeloid leukemia: the PETHEMA Registry Experience","volume":"14","author":"Labrador","year":"2022","journal-title":"Cancers"},{"issue":"3","key":"2025012813454232600_bib21","doi-asserted-by":"crossref","first-page":"e35","DOI":"10.1111\/bjh.18229","article-title":"Hypomethylating agent\/venetoclax versus intensive chemotherapy in adults with relapsed or refractory acute myeloid leukaemia","volume":"198","author":"Jamy","year":"2022","journal-title":"Br J Haematol"},{"key":"2025012813454232600_bib22","doi-asserted-by":"crossref","DOI":"10.1177\/20406207221081637","article-title":"A\u00a0retrospective comparison of salvage intensive chemotherapy versus venetoclax-combined regimen in patients with relapsed\/refractory acute myeloid leukemia (AML)","volume":"13","author":"Park","year":"2022","journal-title":"Ther Adv Hematol"},{"key":"2025012813454232600_bib23","volume-title":"ISCN 1995: an international system for human cytogenetic nomenclature (1995): recommendations of the International Standing Committee on Human Cytogenetic Nomenclature","year":"1994"},{"issue":"4","key":"2025012813454232600_bib24","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1182\/blood-2016-08-733196","article-title":"Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel","volume":"129","author":"D\u00f6hner","year":"2017","journal-title":"Blood"},{"issue":"12","key":"2025012813454232600_bib25","doi-asserted-by":"crossref","first-page":"2795","DOI":"10.1038\/s41375-019-0612-8","article-title":"How we use venetoclax with hypomethylating agents for the treatment of newly diagnosed patients with acute myeloid leukemia","volume":"33","author":"Jonas","year":"2019","journal-title":"Leukemia"},{"issue":"7","key":"2025012813454232600_bib26","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1182\/blood-2017-04-777722","article-title":"Cytarabine dose in the consolidation treatment of AML: a systematic review and meta-analysis","volume":"130","author":"Magina","year":"2017","journal-title":"Blood"},{"issue":"26","key":"2025012813454232600_bib27","doi-asserted-by":"crossref","first-page":"2753","DOI":"10.1182\/blood.2021013626","article-title":"2021 update on MRD in acute myeloid leukemia: a consensus document from the European LeukemiaNet MRD Working Party","volume":"138","author":"Heuser","year":"2021","journal-title":"Blood"},{"key":"2025012813454232600_bib28","author":"R Core Team","year":"2022"},{"issue":"3","key":"2025012813454232600_bib29","doi-asserted-by":"crossref","DOI":"10.1007\/s11864-017-0456-2","article-title":"Treatment of relapsed\/refractory acute myeloid leukemia","volume":"18","author":"Bose","year":"2017","journal-title":"Curr Treat Options Oncol"},{"issue":"8","key":"2025012813454232600_bib30","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1007\/s11864-020-00765-5","article-title":"Treatment of relapsed acute myeloid leukemia","volume":"21","author":"Thol","year":"2020","journal-title":"Curr Treat Options Oncol"},{"issue":"5","key":"2025012813454232600_bib31","doi-asserted-by":"crossref","first-page":"e324","DOI":"10.1016\/S2352-3026(24)00065-6","article-title":"Remission induction versus immediate allogeneic haematopoietic stem cell transplantation for patients with relapsed or poor responsive acute myeloid leukaemia (ASAP): a randomised, open-label, phase 3, non-inferiority trial","volume":"11","author":"Stelljes","year":"2024","journal-title":"Lancet Haematol"},{"issue":"3","key":"2025012813454232600_bib32","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1016\/j.bbmt.2014.11.007","article-title":"Survival of patients with acute myeloid leukemia relapsing after allogeneic hematopoietic cell transplantation: a Center for International Blood and Marrow Transplant Research Study","volume":"21","author":"Bejanyan","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"issue":"suppl 1","key":"2025012813454232600_bib33","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1182\/blood-2022-169509","article-title":"ELN risk stratification is not predictive of outcomes for treatment-na\u00efve patients with acute myeloid leukemia treated with venetoclax and azacitidine","volume":"140","author":"D\u00f6hner","year":"2022","journal-title":"Blood"},{"issue":"4","key":"2025012813454232600_bib34","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1038\/s41408-021-00471-x","article-title":"Prognostic relevance of remission and measurable residual disease status in AML patients prior to reduced intensity or non-myeloablative allogeneic stem cell transplantation","volume":"11","author":"Jentzsch","year":"2021","journal-title":"Blood Cancer J"},{"issue":"8","key":"2025012813454232600_bib35","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1002\/ajh.25514","article-title":"Next-generation sequencing-defined minimal residual disease before stem cell transplantation predicts acute myeloid leukemia relapse","volume":"94","author":"Press","year":"2019","journal-title":"Am J Hematol"},{"issue":"4","key":"2025012813454232600_bib36","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1200\/JCO.2015.63.3826","article-title":"Allogeneic hematopoietic cell transplantation for acute myeloid leukemia: time to move toward a minimal residual disease-based definition of complete remission?","volume":"34","author":"Araki","year":"2016","journal-title":"J\u00a0Clin Oncol"},{"issue":"6","key":"2025012813454232600_bib37","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1158\/2159-8290.CD-22-0939","article-title":"Combinatorial BCL2 family expression in acute myeloid leukemia stem cells predicts clinical response to azacitidine\/venetoclax","volume":"13","author":"Waclawiczek","year":"2023","journal-title":"Cancer Discov"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/9\/2\/375\/2352210\/blooda_adv-2024-013086-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/9\/2\/375\/2352210\/blooda_adv-2024-013086-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,28]],"date-time":"2025-01-28T13:45:59Z","timestamp":1738071959000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/9\/2\/375\/517882\/Venetoclax-based-salvage-therapy-as-a-bridge-to"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,17]]},"references-count":37,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,1,28]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2024013086","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,17]]}}}